Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT01394003 Terminated - Advanced Cancer Clinical Trials

A Study of LY2584702 in Participants With Advanced Cancer

Start date: November 2008
Phase: Phase 1
Study type: Interventional

The main purpose of this trial is to determine a recommended Phase 2 dose of LY2584702 that may be safely administered to participants with advanced/metastatic cancer.

NCT ID: NCT01393990 Completed - Advanced Cancer Clinical Trials

A Study of LY2228820 in Participants With Advanced Cancer

Start date: September 4, 2008
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.

NCT ID: NCT01367795 Completed - Advanced Cancer Clinical Trials

Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life

Start date: July 2010
Phase: N/A
Study type: Observational

Patients in a known palliative setting and with localized symptoms due to tumor growth will be evaluated for their quality of life before and after a surgical intervention (primary endpoint). Medical outcome in terms of length of stay in hospital, length of stay on a intensive care unit, complications, reinterventions will be recorded (secondary endpoints). The investigators will also observe patients with conservative treatment.

NCT ID: NCT01361607 Completed - Pain Clinical Trials

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

SPRAY III
Start date: May 27, 2011
Phase: Phase 3
Study type: Interventional

This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced cancer. Eligible participants were not required to stop any of their current treatments or medications.

NCT ID: NCT01361529 Recruiting - Advanced Cancer Clinical Trials

Safety Study of FLP Injection to Treat Tumor Patients

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for FLP Injection with multiple dose in tumor patients.

NCT ID: NCT01358110 Completed - Metastatic Cancer Clinical Trials

Emergency Department-Based Palliative Care for Advanced Cancer Patients

Start date: May 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to: 1) identify the palliative care needs of Emergency Department patients with advanced cancer, and determine if these needs can be rapidly assessed in the ED; 2) determine whether early palliative care consultation improves survival, quality of life and other burdensome symptoms and decreases utilization as compared to usual care.

NCT ID: NCT01347866 Terminated - Advanced Cancer Clinical Trials

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Start date: October 2011
Phase: Phase 1
Study type: Interventional

After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with ovarian cancer or KRAS mutated non small cell lung cancer for the combination of PF-05212384 plus PD-0325901.

NCT ID: NCT01339871 Completed - Advanced Cancer Clinical Trials

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Start date: April 20, 2011
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

NCT ID: NCT01337089 Completed - Pain Clinical Trials

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Start date: January 19, 2011
Phase: Phase 3
Study type: Interventional

This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.

NCT ID: NCT01313247 Not yet recruiting - Advanced Cancer Clinical Trials

Paracetamol for Cancer Pain

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Randomised, double-blind placebo controlled cross-over trial Main goal: Optimize the medical pain treatment for patients with advanced cancer disease Study goal: Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine > 100 mg/d.